Developmental Research Program

项目总结 淋巴瘤孢子发育研究计划(DRP)的目标是支持创新 翻译研究项目，可能在未来发展为完整的项目。为了实现这一目标， 发展研究计划将征集具有翻译潜力的新项目的提交 淋巴瘤和慢性淋巴细胞性白血病。候选项目将由一个具有翻译研究专业知识的小组进行审查 最有希望的提案将被挑选出来提供支持，目标是它们将发展成为 完整的孢子项目或获得同行评审的资金作为独立项目。中国的领袖们 发展项目将完全纳入孢子，并将能够利用 孢子研究人员将他们的项目从替补席上翻译到床边的专业知识。在过去的4年里， DRP已经支持了来自BCM五个不同部门和中心的11个项目 一个在HMH，以及德克萨斯医疗中心的其他机构(MD Anderson获得一个奖项 癌症中心)和全国(与COG合作颁发一个奖项)。已完成的九个DRP项目 在过去的五年中得到了支持，已经发表了18种出版物，被引用超过1000次，并 已从450 000美元的初始投资中获得525万美元的同行审查资金。这个 项目主任是马尔科姆·布伦纳博士，他继续担任DRP领导人，以及新的联合领导人Dr。 玛格丽特·古德尔和斯蒂芬·戈特沙尔克，他们都是之前的DRP奖获得者。与 管理核心，董事将继续使用该计划来测试和开发新的战略，以 淋巴瘤的治疗，CLL，并将收集数据，以评估DRP计划的成功， 允许内部和外部咨询委员会进行评估。

PROJECT SUMMARY The goal of the Lymphoma SPORE Developmental Research Program (DRP) is to support innovative translational research projects that may in the future develop into full projects. To achieve this objective, the Developmental Research Program will solicit submission of novel projects with translational potential in lymphoma and CLL. Candidate projects will be reviewed by a panel with expertise in translational research and the most promising proposals will be selected for support with the goal that they will either develop into full SPORE projects or secure peer-reviewed funding as independent projects. The leaders of developmental projects will be fully incorporated into the SPORE and will be able to take advantage of the expertise of SPORE investigators in translating their project from the bench to bedside. In the last 4 years, the DRP has supported a broad portfolio of 11 projects from five different departments and centers at BCM and one at HMH, as well as other institutions in the Texas Medical Center (one award to MD Anderson Cancer Center) and nationally (one award in collaboration with COG). The nine completed DRP projects supported in the last five years have already resulted in 18 publications with over 1000 citations and have been leveraged to obtain $5.25 million in peer-reviewed funding from an initial investment of $450,000. The program directors are Dr. Malcolm Brenner, who continues as DRP leader, and new co-leaders Drs. Margaret Goodell and Stephen Gottschalk, who are both previous DRP awardees. In collaboration with the Administrative Core, the directors will continue to use this program to test and develop novel strategies for the treatment of lymphoma, CLL, and will also collect data to evaluate the success of the DRP program, allowing evaluation by the internal and external advisory boards.